Back to search results

Precision T1D Platform for Cardio-Renal Complications

This study is looking for people aged 18 to 75 with Type 1 Diabetes (T1D) who are experiencing heart or kidney problems related to their diabetes. The goal is to test if specific treatments, finerenone or sotagliflozin, can help prevent or slow down these complications. Instead of randomly assigning treatments, your clinical and biomarker data (like EGFR) will be used to match you to the treatment that best fits your unique disease pathways. Researchers will be monitoring your kidney and heart health, as well as any side effects, for 26 weeks to see how safe and effective these treatments are. The study aims to enroll 57 participants.

Study design
This is an open-label pilot study, meaning you and your doctors will know which treatment you are receiving. It will involve about 57 participants, with treatments assigned based on individual disease characteristics rather than randomization.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your kidney and heart health will be monitored for 26 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07594145

Precision T1D Platform - New Therapies for Cardio-Renal Complications

Not Yet Recruiting
PHASE2Ages 18–75InterventionalTreatment
Oregon Health and Science University
~57 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:FinerenoneSotagliflozin

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Markers of Renal Health [Safety and Tolerability]
Measured over 26 weeks
+2 more outcomes measured

Conditions

Type 1 Diabetes
T1D Heart Failure
Cardio-renal Vascular Function and Failure
Diabetic Chronic Kidney Disease

Explore related trials

Diabetic NephropathyHeart FailureType 1 Diabetes Mellitus

Where it's being run

2 sites across 2 states
Michigan1
Oregon1

Study leadership

  • Rodica Busui, MD, PhD · STUDY_CHAIR · Oregon Health and Science University

Who to contact

Laura Nguyen
[email protected]
(971) 509-4222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Markers of Renal Health [Safety and Tolerability]26 weeks

    The primary efficacy endpoints are measures of early (week 26) outcomes on markers of renal health, defined as the percent change from baseline to week 26 in UACR.

  • Markes of Cardio Health [Safety and Tolerability]26 weeks

    The primary efficacy endpoints are measures of early (week 26) outcomes on markers of cardio health as defined by the percent change from baseline to week 26 in NT-proBNP.

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]26 weeks

    The primary safety endpoints are defined as incidence of serious adverse events, adverse events and clinically significant abnormal laboratory tests.